12/29/22 1:46 PMNasdaq : MDWD fda approvallow floatMediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in AdultsPotential to become the new standard of care for eschar removal in patients with deep partial- and/or full- thickness thermal burns Triggers $7.5 million milestone payment from Vericel Corporation; NexoBrid is anticipated to be commercially available in the U.S. in the second quarter of 2023 YAVNE,RHEA-AIvery positive
12/23/22 8:00 AMNasdaq : MDWD low floatMediWound Expands NexoBrid’s Global Presence with Marketing Approval in JapanMediWound Ltd. (Nasdaq: MDWD), a fully integratedRHEA-AIvery positive
12/20/22 8:00 AMNasdaq : MDWD low floatMediWound Strengthens European Presence of NexoBrid®MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generationRHEA-AIvery positive
12/19/22 7:00 AMNasdaq : MDWD low floatMediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell CarcinomaMediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company, focusedRHEA-AIpositive
12/13/22 5:30 AMNasdaq : MDWD low floatMediWound Expands Global Presence as NexoBrid® Gains Approval in IndiaMediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generationRHEA-AIneutral
12/05/22 4:05 PMNasdaq : MDWD low floatMediWound Announces a 1-for-7 Reverse Share SplitMediWound Ltd. (Nasdaq: MDWD) (“ MediWound ” or the “ Company ”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it intends to effect aRHEA-AIpositive
11/15/22 7:00 AMNasdaq : MDWD earningslow float MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update$30.5 million in gross proceeds raised; operating cash runway through 2025 NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company f ocus ed on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-halfRHEA-AIneutral
11/09/22 8:00 AMNasdaq : MDWD low floatMediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUsMediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generationRHEA-AIneutral
11/03/22 8:00 AMNasdaq : MDWD conferencesearningslow floatMediWound to Report Third Quarter 2022 Financial ResultsMediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair andRHEA-AIneutral
10/25/22 7:00 AMNasdaq : MDWD managementlow floatMediWound Announces Formation of Strategic Advisory BoardMediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeuticRHEA-AIneutral